Role of adropin and i̇risin i̇n case of nonalcoholic hepatosteatosis i̇n the preobese and obese i̇ndividuals

NAFLD is a disease that it is seen in healthy people, although it seen more in obese people and type 2 diabetic patients and it is considered to be the hepatic appearance of metabolic syndrome. The aim of this study was to investigate the relationship between serum irisin and adropin levels and hepatosteatosis in preobese and obese adults with NAFLD. Method: A total of 89 individuals were divided into four groups: Group 1; individuals of healthy and normal weight(n=25)(Body mass index; 18,5-24,9), group 2; preobez (BMI; 25-29,9)(n=17) and obese (BMI≥30) individuals without NAFLD, group 3; preobese and obese individuals with grade 1 hepatosteatosis(n=24) and group 4; preobese and obese individuals with grade 2 hepatosteatosis(n=23). Demographic data of all subjects were recorded. Abdominal ultrasonography and anthropometric measurements were performed. Serum adropin and irisin levels were studied by ELISA method. Results: Serum adropin and irisin levels in the group 3 NAFLD and group 4 with NAFLD were found lower than in the group 1 that composed of healthy individuals(p= 0,006, p=0,001 respectively). However serum adropin and irisin levels between the group 3 with NAFLD and group 4 with NAFLD were found similar. Conclusion: Decrease in serum adropin and irisin levels may play a role in the development of NAFLD in preobese and obese individuals regardless of the severity of the disease. But this decrease is not related to severity of disease.